# Jun Guo

Source: https://onco.cc/people/guo-jun/  
OnCo record `guo-jun` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Jun Guo built China's melanoma programme around the acral and mucosal subtypes common in Asia, and led the trials that made toripalimab the first domestic PD-1 antibody approved.

## Summary

Guo's department at Peking University Cancer Hospital is the largest melanoma unit in Asia; he led the registration study of toripalimab in previously treated melanoma (China's first domestic PD-1 approval, December 2018), trials of toripalimab plus axitinib in mucosal melanoma, and work defining KIT and other targets in acral melanoma. Past president of CSCO.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Also known as: 郭军
- Tags: china
- Role: Professor; Department of Renal Cancer and Melanoma, Peking University Cancer Hospital
- Specialisms: Melanoma; Acral and mucosal melanoma; Renal cell carcinoma; Immunotherapy

## Sources

- Peking University Cancer Hospital: https://www.bjcancer.org/
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Guo%20J%5BAuthor%5D%20melanoma%20Peking%20University%20Cancer%20Hospital%20toripalimab

## Connected records

- institutions: [Chinese Society of Clinical Oncology](https://onco.cc/institutions/csco/), [Peking University Cancer Hospital](https://onco.cc/institutions/pku-cancer-hospital/)
- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)

---
JSON: https://onco.cc/api/v1/entities/guo-jun.json